Cover Image
Market Research Report

Circulating Tumor Cells (CTC) Market - Growth, Trends, and Forecast (2019 - 2024)

Published by Mordor Intelligence LLP Product code 649744
Published Content info 112 Pages
Delivery time: 2-3 business days
Price
Back to Top
Circulating Tumor Cells (CTC) Market - Growth, Trends, and Forecast (2019 - 2024)
Published: May 1, 2019 Content info: 112 Pages
Description

Market Overview

The major factors for the growth of the circulating tumor cells (CTC) market include the advancements in biomedical imaging and bioengineering technology, rising demand for preventive medicine and companion diagnostics, and growing prevalence of cancer.

The global cancer burden is increasing, and thus, cancer therapies must be modified according to regional and national priorities. According to the World Cancer Research Fund, in 2018, there were an estimated 18 million cancer cases around the world, out of which, 9.5 million cases were in men and 8.5 million in women. Lung and breast cancers were the most common and contributed about 12.3% of the total number of new cases that were diagnosed in 2018. Almost half of the cancer prevalence occurs in Asia, and in Europe, one-quarter of the population is suffering from cancer. In the Americas, 21% of the population is suffering from cancer. The increasing cancer burden is due to a number of factors, including population growth and aging and the changing prevalence of certain causes of cancer linked to social and economic development. According to the WHO, in 2018, approximately 70% of the deaths in low and middle-income countries were due to cancer. With this growing burden, prevention of cancer is one of the most significant challenges. Furthermore, according to the Globocan Database, in 2018, it was estimated that the number of new cases would grow from 18.1 million to 29.4 million, between 2018 and 2040. Thus, the increasing prevalence of cancer is one of the major factors that are augmenting the growth of the market.

Scope of the Report

As per the scope of this report, circulating tumor cells (CTC) refer to the tumor cells that circulate inside the body through the blood circulatory system and lymphatic system. Factors, such as the high prevalence of cancer, advancements in biomedical imaging and bioengineering technology, and increased demand for preventive medicine, with the need for companion diagnostics, drive the circulating tumor cell market globally. The market is segmented by technology, application, and geography.

Key Market Trends

Negative Enrichment is the Segment by CTC Enrichment Methods is Expected to Dominate the Market

In case of the positive enrichment methods it cannot isolate CTCs depending on heterogeneous properties, but negative enrichment methods can isolate heterogeneous and intact CTCs by specifically eliminating blood cells. The rising prevalence of the various types of cancer is expected to drive the overall growth of the market. The analysis of circulating tumor cells is an increasing interest for monitoring disease progression or response to treatment, specifically as a companion diagnostic for new anticancer drugs, and for research into the mechanisms of disease progression. In addition, negative enrichment has advantages over positive enrichment in isolating CTCs owing to which the market is expected to witness high growth over the forecast period.

North America is Expected to Dominate the Market

In 2018, as per the American Cancer Society, above 15.5% of Americans had a history of cancer by 2016, of which a majority have been diagnosed in the past two years. The highest number of new cases are being reported, such as respiratory system, breast, genital system, and urinary system, with about 1.7 million new cases being reported in 2018. Based on healthcare expenditure, the United States is among the major countries across the world, which spends about 17.1% of its total GDP on healthcare. The expenditure for cancer patients is mostly in breast, lung, and colon and rectum cancers. The United States has one of the highly successful products approved by the US Food and Drug Administration (FDA), CellSearch Circulating Tumor Cell Kit. The product has reimbursement facility through various public and private payers in several states of the country, such as Cigna Government Services, Noridian, and United HealthCare, amongst others. Several universities across the United States, have relied on CTCs applications to advance the practice of pathology and laboratory medicine. Thus, owing to the all above-mentioned factors the market is expected to witness high growth over the forecast period.

Competitive Landscape

The market studied is a moderately consolidated market owing to the presence of small and large market players. Some of the market players are Advanced Cell Diagnostics, Inc, Aviva Biosciences, Biocept Inc, Creatv Micro Tech, Inc., LungLife AI, Inc., Menarini Silicon Biosystems, Miltenyi Biotec, Precision For Medicine formerly ApoCell, and Qiagen NV

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support
Table of Contents
Product Code: 60459

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Advancements in Biomedical Imaging and Bioengineering Technology
    • 4.2.2 Rising Demand for Preventive Medicine and Companion Diagnostics
    • 4.2.3 Growing Prevalence of Cancer
  • 4.3 Market Restraints
    • 4.3.1 Technical Difficulties in Detection and Characterization of CTCs Associated with High Cost of Diagnosis
    • 4.3.2 Lack of Awarness and Unwillingness for the Adoption of Advanced CTC Technologioes
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Technology
    • 5.1.1 CTC Enrichment Methods
      • 5.1.1.1 Positive Enrichment
      • 5.1.1.2 Negative Enrichment
      • 5.1.1.3 Others
    • 5.1.2 CTC Detection Methods
      • 5.1.2.1 Immunocytochemical Technology
      • 5.1.2.2 Molecular (RNA) based Technology
      • 5.1.2.3 Others
  • 5.2 By Application
    • 5.2.1 Multiple Chromosome Abnormalities
    • 5.2.2 RNA Profiling
    • 5.2.3 Protein Expression
    • 5.2.4 Cellular Communication
    • 5.2.5 Other
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Advanced Cell Diagnostics, Inc
    • 6.1.2 Aviva Biosciences
    • 6.1.3 Biocept Inc
    • 6.1.4 Creatv Micro Tech, Inc.
    • 6.1.5 LungLife AI, Inc.
    • 6.1.6 Menarini Silicon Biosystems
    • 6.1.7 Miltenyi Biotec
    • 6.1.8 Precision For Medicine, formerly ApoCell,
    • 6.1.9 Qiagen NV

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top